Drug firm Panacea Biotec today reported a net loss of Rs 71.72 crore for the quarter ended December 31, 2011, mainly due to delisting of the company's pentavalent vaccine by the World Health Organisation (WHO).
The company had posted a net profit of Rs 42.60 crore for the quarter ended December 31, 2010, Panacea Biotec said in a filing to Bombay Stock Exchange (BSE).
"The current performance continues to be affected due to the delisting of the pentavalent vaccine, following a routine site audit by a WHO team in July 2011," Panacea Biotec Joint Managing Director Rajesh Jain said.
Total income of the company stood at Rs 155.16 crore for the quarter under consideration. It was Rs 292.81 crore for the corresponding period in the previous fiscal.
Shares of Panacea Biotec today closed at Rs 89.05 on the BSE, up 0.56% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app